Search Patents
  • PEPTIDE FOR SUPPRESSING CORONAVIRUS AND USE THEREOF
    Publication number: 20230181681
    Abstract: The present invention relates to: a therapeutic composition for coronavirus comprising, as an active ingredient, one peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 6, and SEQ ID NO: 8 that binds to a coronavirus N-protein, a coronavirus-derived spike protein, or a fragment of the spike protein; and a composition that binds to a coronavirus N-protein comprising, as an active ingredient, the coronavirus-derived spike protein or the fragment of the spike protein. It is suggested that the peptides of the present invention, based on the understanding and targeting of the interaction of the coronavirus S protein and N protein of the present invention, have an effect that can be helpful in the treatment of coronaviruses including MERS-CoV, SARS-CoV-2, SARS-CoV, and HCoV-OC43.
    Type: Application
    Filed: May 3, 2021
    Publication date: June 15, 2023
    Inventors: Hyung Joo KWON, Byoung Kwon PARK, Dong Bum KIM, Jin Soo KIM
  • Serine protease inhibitor for treating coronavirus infection
    Patent number: 11045453
    Abstract: The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: June 29, 2021
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • HUMAN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AGAINST CORONAVIRUS SPIKE PROTEIN
    Publication number: 20230312689
    Abstract: It is an object of the present invention to provide antibodies against coronavirus (SARS-CoV-2). It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. According to the present invention, an antibody or antigen-binding fragment thereof that binds to the receptor-binding domain present in the spike protein of coronavirus and is capable of neutralizing the coronavirus, and a pharmaceutical composition for the prevention or treatment of coronavirus infection containing the antibody or antigen-binding fragment, are provided.
    Type: Application
    Filed: July 9, 2021
    Publication date: October 5, 2023
    Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, The University of Tokyo
    Inventors: Shuzo MATSUSHITA, Yu KAKU, Takeo KUWATA, Yoshihiro KAWAOKA, Masaki IMAI, Seiya YAMAYOSHI
  • Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
    Publication number: 20050276818
    Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.
    Type: Application
    Filed: May 17, 2005
    Publication date: December 15, 2005
    Inventors: Adam Godzik, Sergey Sikora
  • Method for treating coronavirus infections
    Patent number: 11779585
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and SARS-CoV-2 infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Grant
    Filed: August 3, 2022
    Date of Patent: October 10, 2023
    Assignee: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • CORONAVIRUS MUTATION DETERMINATION DEVICE COMPRISING METAMATERIAL ARRAY AND ELECTROMAGNETIC WAVE IRRADIATION UNIT
    Publication number: 20240044787
    Abstract: The present specification relates to a device and method capable of determining a coronavirus mutation using a highly sensitive label-free terahertz electromagnetic wave metamaterial sensor, and a device for diagnosing a coronavirus disease-19, amd the device can specify the amino acids of a virus belonging to the genus coronavirus having an excellent absorption in a terahertz band, and the metamaterial can amplify the corresponding signal, and the problem of coffee ring formation, which hinders the measurement and analysis in the conventional measurement and analysis of solution-based samples, can be solved by the method in which a sample containing coronavirus is applied to the surface of a metamaterial, and the optical constant value of the sample is analyzed, so that it is possible to more quickly and accurately determine the coronavirus mutation, and furthermore, there is an excellent effect in diagnosing a coronavirus disease-19.
    Type: Application
    Filed: August 4, 2023
    Publication date: February 8, 2024
    Inventors: Minah SEO, Hyun Seok SONG, Hyun Gyu SONG, Jeongmin JANG, Yeonkyung LEE, Soohyun LEE
  • Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
    Patent number: 7504205
    Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: March 17, 2009
    Assignee: The Burnham Institute
    Inventors: Adam Godzik, Sergey Sikora
  • CORONAVIRUS INFECTION THERAPEUTIC AGENT FORMED THROUGH COMBINATION OF PYRAZINE DERIVATIVE AND ANOTHER CORONAVIRUS INFECTION THERAPEUTIC DRUG
    Publication number: 20230210848
    Abstract: An object of the present invention is to provide a novel combination of substances showing effects against coronavirus. The present invention provides a therapeutic agent for coronavirus infection comprising a combination of a pyrazine derivative or a salt thereof and another therapeutic agent for coronavirus infection.
    Type: Application
    Filed: April 27, 2021
    Publication date: July 6, 2023
    Applicant: FUJIFILM TOYAMA CHEMICAL CO., LTD.
    Inventors: Takashi KOMENO, Nozomi YAMASHITA
  • SYSTEM FOR SCREENING THERAPEUTIC AGENTS FOR CORONAVIRUS INFECTION
    Publication number: 20230242901
    Abstract: The present invention relates to a screening composition for a therapeutic agent for coronavirus infection, comprising a CoV RdRp expression vector and a bicistronic reporter vector, a screening kit for a therapeutic agent for coronavirus infection, comprising the composition, and a method for screening a therapeutic agent for coronavirus infection using the composition or kit. When the screening composition for a therapeutic agent for coronavirus infection, provided by the present invention, is used, candidate materials that can have direct influences on the activity of CoV RdRp can be screened more quickly and easily, and thus, the composition can be widely used in the development of therapeutic agents for coronavirus infection.
    Type: Application
    Filed: September 29, 2020
    Publication date: August 3, 2023
    Inventors: Sun Oh KWON, Young Hee JIN, Jung Sun MIN
  • Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
    Patent number: 11471448
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: October 18, 2022
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi, Mark Levitt, Ofra Barnett
  • Methods And Compositions For Treating Coronavirus
    Publication number: 20220088403
    Abstract: Disclosed are methods of inhibiting a coronavirus from infecting or replicating in a cell comprising exposing the cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, wherein the frequency and field strength of the alternating electric field inhibits coronavirus infection or replication. Disclosed are methods of reducing coronavirus copy number per cell comprising exposing the cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, wherein the frequency and field strength of the alternating electric field reduces coronavirus copy number in the cell. Disclosed are methods of treating a subject infected with coronavirus comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more coronavirus infected cells.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 24, 2022
    Inventors: Tali Voloshin-Sela, Lilach Avigdor, Yaara Porat, Moshe Giladi, Helena Are Yaara, Helena Mumblat
  • Method for treating coronavirus infections
    Patent number: 11738025
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: August 29, 2023
    Assignee: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • USE OF TWO-DIMENSIONAL NANOMATERIAL IN INHIBITION OF CORONAVIRUS
    Publication number: 20240091167
    Abstract: Provided is the use of two-dimensional nanomaterials in the inhibition of a coronavirus, and specifically disclosed is the use of the two-dimensional nanomaterials in the preparation of a medicament for treating or preventing diseases caused by a coronavirus or of a material for adhering to or inhibiting the coronavirus. The two-dimensional nanomaterial is selected from the group consisting of copper indium thiophosphate (CIPS) nanosheet, graphene oxide nanosheet, molybdenum disulfide nanosheet, black phosphorus nanosheet and mixtures thereof. The coronavirus is selected from one of HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, SARS-CoV2 or MERS-CoV. The diseases caused by the coronavirus are diseases caused by coronavirus infection. The material has the advantages of being simple to prepare, having a high biological safety and an excellent effect.
    Type: Application
    Filed: December 22, 2021
    Publication date: March 21, 2024
    Applicants: SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY, INSTITUTE OF HIGH ENERGY PHYSICS, CAS
    Inventors: Yang LI, Liming WANG, Guofang ZHANG
  • Serine protease inhibitor for treating coronavirus infection
    Patent number: 11918560
    Abstract: The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: March 5, 2024
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • APPLICATION OF GOSSYPOL AND ITS OPTICAL ISOMERS TO PREPARATION OF CORONAVIRUS 3CL PROTEASE INHIBITOR
    Publication number: 20240074990
    Abstract: The present invention relates to application of gossypol and its optical isomers to preparation of an anti-Coronavirus drug. Specifically disclosed is application of pharmaceutically acceptable salts, solvates, isotopes, stereoisomers, stereoisomer mixtures, and tautomers of the gossypol and its optical isomers to preparation of a drug for preventing and/or treating a disease caused by a Coronavirus. The Coronavirus is MERS-CoV, SARS-CoV, or SARS-CoV-2. It is found in the present invention for the first time that the gossypol and its optical isomers can inhibit the activity of Coronavirus 3CL proteases to achieve an anti-Coronavirus effect. The half maximal inhibitory concentrations of gossypol and (?)-gossypol to SARS-CoV proteases and SARS-CoV-2 3CL proteases are all lower than 10 ?M. The anti-Coronavirus 3CL protease effect is good. Therefore, the gossypol and its optical isomers have the potential for use in the preparation of a drug for preventing and/or treating novel Coronavirus infections.
    Type: Application
    Filed: March 18, 2023
    Publication date: March 7, 2024
    Inventors: Xiaolin XIE, Dezhu ZHANG, Zhao MA, Boyang LI, Xuhua ZHOU, Lei TIAN, Chengyuan LIANG, Taotao QIANG, Jingyi LI, Liang XIN, Shaojun ZHANG, Kangxiong WU, Xiuding YANG, Sundian LIU, Yuting LIU
  • METHOD AND SYSTEM FOR MANAGING CORONAVIRUS SCREENING OPERATIONS
    Publication number: 20220142619
    Abstract: A method may include determining whether to perform a coronavirus diagnostic test on a member of a predetermined population. The method may further include sending, in response to determining that the coronavirus diagnostic test should be performed on the member, a coronavirus testing kit to the member. The coronavirus testing kit may include a return shipping container, a substrate, and a specimen transport container configured to store a biological specimen. The method may further includes determining whether the biological specimen is received at a laboratory facility from the member. The method may further include transmitting, to at least one user device associated with the member, a notification regarding a coronavirus infection diagnosis based on the biological specimen.
    Type: Application
    Filed: November 12, 2021
    Publication date: May 12, 2022
    Applicant: LUCE COMMUNICATIONS LLC
    Inventors: Daniel Robert Ablett, Joel Nathanael Luce
  • CORONAVIRUS VACCINE
    Publication number: 20210322541
    Abstract: Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain. The coronavirus protein may be the receptor binding domain of the S1 subunit of coronavirus spike (S) protein. The polynucleotide such as RNA is useful for as a vaccine against coronavirus infection, especially, COVID-19 infection.
    Type: Application
    Filed: April 16, 2021
    Publication date: October 21, 2021
    Applicant: VLP Therapeutics, Inc.
    Inventors: Wataru AKAHATA, Jonathan F. SMITH, Ryuji UENO
  • Inactivated canine coronavirus vaccine
    Patent number: 4567042
    Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed.
    Type: Grant
    Filed: June 7, 1984
    Date of Patent: January 28, 1986
    Assignee: American Home Products Corporation
    Inventors: William M. Acree, Bobby Edwards, John W. Black
  • Protease Inhibitors for Treatment or Prevention of Coronavirus Disease
    Publication number: 20230192660
    Abstract: Provided are protease inhibitor compounds that find use in treating or preventing coronavirus disease. In some embodiments, the coronavirus disease is COVID-19. Also provided are compositions and kits comprising the compounds, as well methods of using the compounds to treat or prevent coronavirus disease. Methods of assessing inhibition of coronavirus protease activity by an agent are also provided.
    Type: Application
    Filed: May 7, 2021
    Publication date: June 22, 2023
    Inventors: Michael Z. Lin, Xinzhi Zou, Michael Westberg Soerensen, Lin Ning, Yichi Su
  • Lateral Flow Devices for High Sensitivity Detection of Coronavirus Infection, and Methods of Making and Using the Same
    Publication number: 20240019426
    Abstract: The present disclosure provides, inter alia, a lateral flow device, and methods of use of the device, for accurately and rapidly detecting the presence of a coronavirus or a coronavirus infection in a subject, such as a SARS-CoV-2 virus or virus infection. The lateral flow device detects in a sample from the subject the presence or absence of a coronavirus protein (e.g., a SARS-CoV-2 protein), such as an S protein, an Si protein, or nucleocapsid protein. The lateral flow device comprises, for example, Pt or Au/Pt nanoparticle-antibody conjugates for detection of coronavirus protein or coronavirus infection, such as a SARS-CoV-2 protein or a SARS-CoV-2 infection.
    Type: Application
    Filed: November 3, 2021
    Publication date: January 18, 2024
    Applicant: Sorrento Therapeutics, Inc.
    Inventor: Henry Hongjun Ji
Narrow Results

Filter by US Classification